Determine MTD, Evaluate Efficacy and Safety of Genexol®-PM Plus Carboplatin With Advanced Ovarian Cancer

NCT00877253 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: Genexol-PM 220mg/㎡, Carboplatin 5AUC
DRUG: Genexol-PM 260mg/㎡, Carboplatin 5AUC
DRUG: Genexol-PM 300mg/㎡, Carboplatin 5AUC

Sponsor

Samyang Biopharmaceuticals Corporation